Pathogenics’ core operational strengths are the expertise and successful track records of its business management and scientific development team. This management team has particular expertise in biopharmaceutical development and licensing, and have been involved in the establishment and management of several small biopharmaceutical companies. The Company’s scientific development team are a well-rounded group of respected international academic researchers, leading clinical investigators, and experienced biopharmaceutical advisors and consultants.
Officers & Directors
Research Scientists & Clinicians
Scientific Consultants
Officers & Directors
Frederic P. Zotos, Esq., President & CEO
 Frederic P. Zotos has served as President and Chief Executive Officer, Secretary, Treasurer and Director of the Company since February 18, 2005. Mr. Zotos has served as managing member of the Company's wholly owned subsidiary Pathogenic, LLC, since its creation on November 19, 2002. Mr. Zotos brings to the Company his proven skills in patent licensing and business development, technology management and corporate finance. Prior to forming Pathogenics, LLC, Mr. Zotos served as Director of Atlantic Technology Ventures, Inc. ("Atlantic” formerly NASDAQ Smallcap: ATLC and OTC BB: ATLC.OB) from May 1999 to February 2003, President of Atlantic from April 2000 to February 2003, and Chief Executive Officer of Atlantic from February 2001 until his departure upon successfully merging the company in February 2003.
From June 1999 to March 2000, Mr. Zotos served as Director of due diligence for Licent Capital, LLC, an intellectual property royalty finance company located in Jericho, New York. From November 1996 to August 1998, Mr. Zotos served as Assistant to the President and Patent Counsel for Competitive Technologies, Inc. (AMEX: CTT), a technology licensing agency located in Fairfield, Connecticut. From June 1994 to October 1996, Mr. Zotos served as an Associate Attorney at Law with the law firm of Pepe and Hazard, a general practice law firm located in Hartford, Connecticut. From January 1988 to August 1989 Mr. Zotos was a Project Engineer, Military OEM with Barry Controls Corporation, Brighton, Massachusetts.
Mr. Zotos has served on the board of directors for several companies including, Gemini Technologies, Inc. (anti-sense gene therapy drugs); Optex Ophthalmologics, Inc. (ophthalmic surgery devices); Channel Therapeutics, Inc. (analgesic and anti-inflammatory therapeutic compounds); and Tera Comm Research, Inc. (superconducting electronic fiber-optic transceivers).
Mr. Zotos is a registered patent attorney with the United States Patent and Trademark Office, and is also registered to practice law in Massachusetts and Connecticut. He is an active member of the Licensing Executives Society and a current member of the Boston Patent Law Association. Mr. Zotos received a Bachelors degree in Mechanical Engineering from Northeastern University in 1988, a Masters Degree in Business Administration and a Juris Doctorate from Northeastern University in 1993, and successfully completed an M.S. in Electrical Engineering Prerequisite Program in 1994.
Back To Menu
Michael L. Ferrari, Vice-President
Michael Ferrari has served as Vice President of Research and Business Development and Director of the Company since February 18, 2005. Since its creation on November 19, 2002, Mr. Ferrari has served as a member of the Company's wholly owned subsidiary Pathogenic, LLC. Since March 2004, Mr. Ferrari has been employed by Clinical Advisors, LLC, as head of operations, sales and project management. From August 2003 to February 2004, Mr. Ferrari served as a private equity associate with Maxim Group, LLC. From January 2001 to January 2003, Mr. Ferrari served as Vice President of Business Development for Atlantic Technology Ventures. From September 1998 to January 2001, Mr. Ferrari served as Manager of Business Development at Corporate Technology Development, Inc. From September 1997 to September 1998, Mr. Ferrari worked for Aetna U.S. Healthcare as an Account Executive. Mr. Ferrari received his Bachelors degree in Biology from Villanova University in 1997. Mr. Ferrari holds series 7 and 63 securities licenses. He has also been a member of the Licensing Executive Society since 1999.
Back To Menu
Research Scientists & Clinicians
Waldemar Gottardi, Ph.D.
Waldemar Gottardi, Ph.D., is the inventor of the anti-infective sodium salt form of N-chlorotaurine. He is an Associate Professor in technical Hygiene at the University of Innsbruck, Institute of Hygiene and Social Medicine, Department of Hygiene located in Innsbruck, Austria. His relevant research interests include the areas of: (1) chemical disinfection – basic research on microbicidal action of iodine and active chlorine compounds; (2) clinical application of endogenous oxidants – clinical trials on the tolerability and efficacy of N-chlorotaurine in topical treatment of infections; and, (3) anitimicrobial agents – in vitro and in-vivo activity of disinfectants, interactions of these agents with innate immunity. Dr. Gottardi has authored numerous scientific papers on these subjects, and has been the recipient of research grants from the Austrian Science Fund, Austrian National Bank and the Legerlotz-Foundation.
Back To Menu
Markus Nagl, Ph.D.
Markus Nagl, Ph.D., is a co-inventor of the anti-infective properties of N-Chlorotaurine. He is an Associate Professor for Hygiene and Microbiology at the University of Innsbruck, Institute of Hygiene and Social Medicine, Department of Hygiene located in Innsbruck, Austria. His relevant research interests include the areas of: (1) innate immunity; intracellular killing of pathogens by leukocytes – functions of oxidants in intracellular killing, direct activity of endogenous oxidants (N-chlorotaurine) against pathogens; (2) clinical application of endogenous oxidants – clinical trials of the tolerability and efficacy of N-chlorotaurine in topical treatment of infections, e.g. conjunctivitis, otitis and sinusitis, leg ulcer, cystitis; and, (3) antimicrobial agents (antibiotics, disinfectants . . . ) and interaction of these agents with innate immunity. Dr. Nagl has authored numerous scientific papers on these subjects, and has been the recipient of research grants from the Austrian Science Fund, Austrian National Bank and the Legerlotz-Foundation. He is also the winner of the Austrian Hygiene Prize (1999), and has been a repeat Academic visitor at the Rayne Institute, Centre for Molecular Medicine, University College London.
Back To Menu
Barbara Teuchner, MD
Barbara Teuchner, MD, is a co-inventor of the method of using the anti-infective N-Chlorotaurine to treat ophthalmic infections such as viral conjunctivitis (”pink eye”). She is a staff member of the Department of Ophthalmology, Innsbruck Medical University, Innsbruck, Austria.
Back To Menu
Scientific Consultants
Robert A. Abrahams, Ph.D.
Robert A. Abrahams, Ph.D., serves as a technical consultant to Pathogenics on anti-microbial and disinfection technologies. He is founder and principal of Technology Management Network, LLC, a firm engaged in business development, technology licensing and product development serving the medical device and pharmaceutical industries. Prior to forming Technology Management Network, Dr. Abrahams served as vice president of sales and marketing for Alcide Corporation, a specialty antimicrobial pharmaceutical company. In addition to several other positions, Dr. Abrahams served as director of contact lens and eye care products for Bausch & Lomb, Inc., and was responsible for the development and introduction of the highly successful Renu line of contact lens products. Dr. Abrahams earned a B.S. in Chemistry from Queens College in 1963, a Ph.D. in Physical Chemistry from Polytechnic Inst. of Brooklyn in 1970, and an M.B.A. in Marketing from Fordham University Graduate School of Business in 1975.
Back To Menu
|
